drugset / Trial / NCT01986920

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920

Phase 1/2 Completed 35 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.

Timeline

Start
2013-10-22
Primary completion
2014-02-25
Completion
2014-02-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrogen Peroxide Small molecule 25 %
Comparator Hydrogen Peroxide Small molecule 32.5 %
Comparator Hydrogen Peroxide Small molecule 40 %

Indications